Figure 2From: Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor Kaplan-Meier of cumulative survival of patients excluding those lost to follow-up. The cumulative survival of patients, excluding those lost to follow-up, enrolled in GIPAP is shown.Back to article page